Ash 2022 – toxicity still looms large for Regeneron's bispecific | Evaluate

Retrieved on: 2022-12-11 19:28:03

Tags for this article:

RTT

Medical specialties

Click the tags to see associated articles and topics

Ash 2022 – toxicity still looms large for Regeneron's bispecific | Evaluate. View article details on HISWAI: https://www.evaluate.com/vantage/articles/events/conferences/ash-2022-toxicity-still-looms-large-regenerons-bispecific

Excerpt

Regeneron was already behind Abbvie and Genmab's similarly acting epcoritamab and Roche's glofitamab, and facing questions about how it might ...

Article found on: www.evaluate.com

View Original Article